Nature Medicine Commission on dialysis policy in low- and middle-income countries
- PMID: 41566046
- DOI: 10.1038/s41591-025-04084-w
Nature Medicine Commission on dialysis policy in low- and middle-income countries
Abstract
The global demand for kidney replacement therapy (KRT) continues to increase, yet access remains limited in many low- and middle-income countries. Thailand has been recognized for integrating a sustainable KRT delivery model into its Universal Health Coverage scheme through a peritoneal dialysis-first ('PD-First') policy adopted in 2008. In 2022, the policy was revised to allow individuals to choose between hemodialysis or peritoneal dialysis as their first-line treatment. The intention was to improve patient choice and avoid high out-of-pocket costs, but the policy produced unintended consequences for the health system and patients. A Commission was convened to first assess the impact of the policy change and provide policy recommendations to the Thai government and, second, provide lessons for countries working to expand equitable access to KRT within national universal health coverage frameworks. Drawing on empirical data, the Commission-composed of Thai and international multidisciplinary experts-employed a structured deliberative process to inform policy interventions. The process and findings underscore the importance of participatory policymaking, underpinned by evidence and a systematic process, and monitoring and evaluation in managing complex policy transitions.
© 2026. Springer Nature America, Inc.
Conflict of interest statement
Competing interests: V.J. has received consulting fees or honoraria from Bayer, AstraZeneca, Boehringer Ingelheim, Vera, Visterra, Otsuka, Novartis, Chinook, Biocryst and Alpine under the policy of all payments going to the George Institute for Global Health. T.K. has received consultancy fees from Visterra, Otsuka and AstraZeneca as a country investigator and is currently a recipient of a grant from the National Research Council of Thailand. T.K. has also received speaking honoraria from AstraZeneca, Alexion, Fresenius Medical Care and Baxter Healthcare. S.C.W.T. has received consulting fees or honoraria from Astra Zeneca, Bayer, Boehringer Ingelheim, Everest Medicines, Novartis and Vantive. The other authors declare no competing interests.
References
-
- ISN–Global Kidney Health Atlas: A Report by the International Society of Nephrology: An Assessment of Global Kidney Health Care Status Focusing on Capacity, Availability, Accessibility, Affordability and Outcomes of Kidney Disease (International Society of Nephrology, 2023); https://www.theisn.org/initiatives/global-kidney-health-atlas/
-
- Irish, G. L. et al. Breakthrough discoveries. ISN https://www.theisn.org/about-isn/history/breakthrough-discoveries/#break... (2020).
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
